Alpheus Medical Launches Phase 2b Trial for Novel Glioblastoma Therapy Using Ultrasound-Activated Drug Approach
Key Insights
Alpheus Medical (search) has initiated a Phase 2b randomized controlled trial for newly diagnosed glioblastoma (search) patients, enrolling 10 patients to date with additional clinical sites coming online.
The investigational therapy uses Porphyrin Metabolite Activation (search) (PoMA (search)), previously known as Sonodynamic Therapy (search), which combines a tumor-targeting molecule with low-intensity ultrasound activation.
The multi-center trial will enroll over 100 patients at up to 15 U.S. and European sites, comparing standard of care alone versus standard of care plus the investigational therapy.
Alpheus Medical (search), a private clinical-stage biotechnology company, has launched its Phase 2b randomized controlled trial evaluating a novel therapeutic approach for newly diagnosed glioblastoma (search) (nGBM), with 10 patients enrolled to date and additional clinical sites continuing to come online.
The investigational therapy addresses a fundamental challenge in glioblastoma (search) treatment: the highly infiltrative nature of these brain tumors, where cancer cells extend beyond visible tumor margins and spread throughout the brain hemisphere, limiting the effectiveness of surgery and localized therapies.
Novel Therapeutic Mechanism
The Alpheus study is evaluating an investigational therapy based on Porphyrin Metabolite Activation (search) (PoMA (search)), an approach previously described in clinical literature as Sonodynamic Therapy (search) (SDT (search)). This drug-centered approach leverages a molecule that preferentially accumulates in tumor cells, followed by activation using low-intensity ultrasound to enable localized pharmacologic effects. The treatment is designed to act within tumor cells throughout the affected hemisphere.
"Glioblastoma (search) patients have few effective treatment options and poor long-term outcomes, highlighting the urgent need for innovation," said David Reardon, MD, Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, and Principal Investigator of the study. "Alpheus' approach is designed to address the diffuse nature of the disease by enabling treatment across the affected hemisphere. We look forward to generating data to understand its potential role in patient care."
Clinical Trial Design
The Phase 2b study (NCT07225621) is a multi-center, randomized trial expected to enroll more than 100 newly diagnosed high-grade glioma (search) patients at up to 15 U.S. and European sites. Eligible patients have undergone resection and standard radiochemotherapy. The study compares standard of care alone to standard of care plus investigational therapy.
The primary endpoint is progression-free survival (PFS) with key secondary endpoints including overall survival (OS), safety, and tolerability. The non-invasive approach is intended to activate the molecule directly within tumor cells while minimizing systemic exposure.
Company Leadership Perspective
"The Phase 2b trial marks an important step forward in bringing our new therapeutic approach to patients with glioblastoma (search)," said Vijay Agarwal, MD, FAANS, FCNS, Chief Executive Officer of Alpheus Medical (search). "We believe our drug-centered approach has the potential to address the diffuse nature of the disease in ways that localized treatment cannot. With strong early enrollment, we are focused on generating the randomized clinical data to advance this therapy."
The therapeutic strategy uses low-intensity, diffuse ultrasound designed to enable treatment across the affected hemisphere, achieving localized pharmacologic effects while potentially addressing the diffuse nature of the disease that characterizes glioblastoma (search).